

Title (en)

PHARMACEUTICAL COMPOSITION HAVING REDUCED TENDENCY FOR DRUG CRYSTALLIZATION

Title (de)

ARZNEIMITTEL MIT REDUZIERTER NEIGUNG ZUR KRISTALLISIERUNG

Title (fr)

COMPOSITION PHARMACEUTIQUE AYANT UNE TENDANCE REDUITE A LA CRISTALLISATION DES MEDICAMENTS

Publication

**EP 1365812 A2 20031203 (EN)**

Application

**EP 02709027 A 20020115**

Priority

- US 0200971 W 20020115
- US 26255501 P 20010118
- US 28460801 P 20010417

Abstract (en)

[origin: WO02056878A2] An orally deliverable pharmaceutical composition is provided comprising a drug of low water solubility, a solvent liquid that comprises at least one pharmaceutically acceptable solvent, and a turbidity-decreasing polymer, wherein (a) a substantial portion, for example at least about 15 % by weight, of the drug is in dissolved or solubilized form in the solvent liquid, and (b) the polymer is present in an amount sufficient to substantially inhibit crystallization and/or precipitation of the drug in simulated gastric fluid.

IPC 1-7

**A61K 47/38**

IPC 8 full level

**A61K 9/08** (2006.01); **A61K 9/107** (2006.01); **A61K 9/48** (2006.01); **A61K 31/00** (2006.01); **A61K 31/122** (2006.01); **A61K 31/337** (2006.01); **A61K 31/352** (2006.01); **A61K 31/365** (2006.01); **A61K 31/415** (2006.01); **A61K 31/42** (2006.01); **A61K 31/444** (2006.01); **A61K 31/50** (2006.01); **A61K 31/52** (2006.01); **A61K 31/522** (2006.01); **A61K 45/00** (2006.01); **A61K 47/30** (2006.01); **A61K 47/32** (2006.01); **A61K 47/34** (2006.01); **A61K 47/38** (2006.01); **A61P 25/04** (2006.01); **A61P 25/06** (2006.01); **A61P 29/00** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP KR US)

**A61K 9/1075** (2013.01 - EP US); **A61K 9/4816** (2013.01 - EP US); **A61K 9/4858** (2013.01 - EP US); **A61K 9/4866** (2013.01 - EP US); **A61K 31/00** (2013.01 - EP US); **A61K 31/122** (2013.01 - EP US); **A61K 31/337** (2013.01 - EP US); **A61K 31/352** (2013.01 - EP US); **A61K 31/365** (2013.01 - EP US); **A61K 31/415** (2013.01 - EP US); **A61K 31/42** (2013.01 - EP US); **A61K 31/444** (2013.01 - EP US); **A61K 31/50** (2013.01 - EP US); **A61K 31/52** (2013.01 - EP US); **A61K 47/30** (2013.01 - KR); **A61P 25/04** (2017.12 - EP); **A61P 25/06** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **B82Y 5/00** (2013.01 - EP US)

Citation (search report)

See references of WO 02056878A2

Citation (examination)

- WO 02083177 A1 20021024 - PHARMACIA CORP [US], et al
- WO 02102376 A1 20021227 - PHARMACIA CORP [US], et al

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

**WO 02056878 A2 20020725**; **WO 02056878 A3 20021219**; AR 035735 A1 20040707; BR 0206580 A 20031216; CA 2434338 A1 20020725; CN 100335136 C 20070905; CN 1498114 A 20040519; CZ 20031844 A3 20031217; EA 006383 B1 20051229; EA 200300752 A1 20040226; EP 1365812 A2 20031203; HK 1065959 A1 20050311; IL 156916 A0 20040208; JP 2004520359 A 20040708; KR 20030070118 A 20030827; MX PA03006357 A 20031006; NO 20033244 D0 20030717; NO 20033244 L 20030917; NZ 526976 A 20050225; PE 20020799 A1 20020911; PL 363215 A1 20041115; US 2002156124 A1 20021024; US 2003045563 A1 20030306; US 7115565 B2 20061003

DOCDB simple family (application)

**US 0200971 W 20020115**; AR P020100196 A 20020118; BR 0206580 A 20020115; CA 2434338 A 20020115; CN 02806766 A 20020115; CZ 20031844 A 20020115; EA 200300752 A 20020115; EP 02709027 A 20020115; HK 04108957 A 20041112; IL 15691602 A 20020115; JP 2002557386 A 20020115; KR 20037009549 A 20030718; MX PA03006357 A 20020115; NO 20033244 A 20030717; NZ 52697602 A 20020115; PE 2002000019 A 20020115; PL 36321502 A 20020115; US 4722202 A 20020115; US 4790202 A 20020114